Phase I dose escalation study of HFB200603, a best-in-class BTLA antagonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS) in adult patients (pts) with advanced solid tumors

被引：0
|
作者：
De Miguel, M. [1 ]
Landa Magdalena, A. [2 ]
Moreno Garcia, V. [3 ]
Gambardella, V. [4 ]
Menis, J. [5 ]
Daniele, G. [6 ]
El-Khoueiry, A. B. [7 ]
Spira, A. I. [8 ]
Gravina, A. [9 ,10 ]
Olszanski, A. J. [11 ]
Rapaic, O. [12 ]
Li, J. [13 ]
Poullain, H. [14 ]
Margall, G. [14 ]
Wong, G. [15 ]
Hedrich, W. [16 ]
Pollard, J. Russella [15 ]
Gan, J. [17 ]
Shi, X. [18 ]
Andtbacka, R. H. I. [19 ]
机构：
[1] Hosp Univ HM Sanchinarro, CIOCC Ctr Integral Oncol Clara Campal, Early Phase Clin Trial Unit, Madrid, Spain
[2] Clin Univ Navarra, Dept Med Oncol, Madrid, Spain
[3] Hosp Univ Fdn Jimenez Diaz, START Madrid FJD Early Phase Clin Trials Unit, Madrid, Spain
[4] Hosp Clin Univ Valencia, Med Oncol, Valencia, Spain
[5] AOU Integrata Verona Osped Borgo Roma, Med Oncol, Verona, Italy
[6] Fdn Policlin Univ Agostino Gemelli IRCCS, Phase Unit 1, Rome, Italy
[7] USC Univ Southern Calif, Keck Sch Med, Med Oncol Div, Los Angeles, CA USA
[8] Virginia Canc Specialist, Res Dept, Fairfax, VA USA
[9] Ist Nazl Tumori IRCCS Fdn G Pascale, Dipartimento Ric Traslaz, Naples, Italy
[10] Ist Nazl Tumori IRCCS Fdn G Pascale, Serv Percorsi Oncol, Naples, Italy
[11] Fox Chase Canc Ctr, Hematol Oncol, Philadelphia, PA USA
[12] HiFiBiO Inc, Clin Operat, Cambridge, MA USA
[13] HiFiBiO Therapeut Inc, Dis Biol, Cambridge, MA USA
[14] HiFiBio SAS, Translat Med, Paris, France
[15] HiFiBiO Therapeut Inc, Translat Med, Cambridge, MA USA
[16] HiFiBiO Therapeut Inc, Clin Pharmacol, Cambridge, MA USA
[17] HiFiBiO Therapeut Inc, Res, Cambridge, MA USA
[18] HiFiBiO Therapeut, Clin Dev, Shanghai, Peoples R China
[19] HiFiBiO Therapeut Inc, Clin Dev, Cambridge, MA USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1065
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1006P
引用
收藏
页码：S684 / S684
页数：1
相关论文
共 50 条
  • [31] Preliminary results from subsets of patients (pts) with advanced gastric cancer (GC) and esophageal carcinoma (EC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)
    Desai, J.
    Millward, M.
    Chao, Y.
    Gan, H.
    Voskoboynik, M.
    Markman, B.
    Townsend, A.
    Atkinson, V.
    Zhu, A.
    Song, J.
    Qi, Q.
    Kang, A.
    Deva, S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [32] Phase 1 first-in-human study of anti-ILT3 mAb MK-0482 as monotherapy and in combination with pembrolizumab in advanced solid tumors: Dose escalation results
    Gutierrez, Martin
    Spreafico, Anna
    Wang, Ding
    Golan, Talia
    Renouf, Daniel
    Voskoboynik, Mark
    Chatterjee, Manash Shankar
    Kapadia, Kishan J.
    Liu, Qi
    Kovvali, Gopala
    Suttner, Leah
    Pang, Ling
    Chen, Mei
    Tolcher, Anthony W.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] A phase Ia/Ib trial of the anti-PD-L1 human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumors or lymphomas.
    Shen, Lin
    Cao, Junning
    Li, Jin
    Pan, Hongming
    Xu, Nong
    Zhang, Yan
    Wang, Jingru
    Wang, Yin
    Dai, Hangjun
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [34] Open-label, phase I, dose escalation/expansion trial of the anti-SIRPa monoclonal antibody BI 770371 in patients with advanced solid tumours, alone or in combination with the anti-PD-1 monoclonal antibody ezabenlimab
    Gutierrez, M.
    Jamal, R.
    Yamamoto, N.
    Doi, T.
    Elgadi, M.
    Ferrada, J. L.
    Wojciekowski, S. M.
    Patel, M. R.
    ANNALS OF ONCOLOGY, 2023, 34 : S485 - S485
  • [35] A phase 1 study of serplulimab, a novel humanized monoclonal anti-PD-1 antibody, in patients with advanced solid tumors.
    Ho, Ching-Liang
    Chao, Tsu-Yi
    Chang, Chia Lun
    Lin, Hsuan-Yu
    Yang, Futang
    Wang, Qingyu
    Zhu, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [36] A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or Lymphoma
    Gong, Jifang
    Guo, Ye
    Zhang, Yanqiao
    Ba, Yi
    Chen, Tong
    Li, Wei
    Zhou, Caicun
    Wang, Mengzhao
    Yang, Haiyan
    Zhou, Yuhong
    Cai, Qiqing
    Wang, Ziping
    Huang, Gang
    Zhang, Wei
    Su, Rila
    Cai, Zhongheng
    Yue, Zenglian
    Dou, Jinzhou
    Li, Peiqi
    Wu, Rachel
    Tse, Archie N.
    Shen, Lin
    TARGETED ONCOLOGY, 2024, 19 (05) : 723 - 733
  • [37] A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors
    Naing, Aung
    Gainor, Justin F.
    Gelderblom, Hans
    Forde, Patrick M.
    Butler, Marcus O.
    Lin, Chia-Chi
    Sharma, Sunil
    de Olza, Maria Ochoa
    Varga, Andrea
    Taylor, Matthew
    Schellens, Jan H. M.
    Wu, Hongqian
    Sun, Haiying
    Silva, Antonio P.
    Faris, Jason
    Mataraza, Jennifer
    Cameron, Scott
    Bauer, Todd M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [38] Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies
    Naing, Aung
    Infante, Jeffrey
    Goel, Sanjay
    Burris, Howard
    Black, Chelsea
    Marshall, Shannon
    Achour, Ikbel
    Barbee, Susannah
    May, Rena
    Morehouse, Chris
    Pollizzi, Kristen
    Song, Xuyang
    Steele, Keith
    Elgeioushi, Nairouz
    Walcott, Farzana
    Karakunnel, Joyson
    LoRusso, Patricia
    Weise, Amy
    Eder, Joseph
    Curti, Brendan
    Oberst, Michael
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01):
  • [39] First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors
    Shimizu, Toshio
    Powderly, John
    Abdul Razak, Albiruni
    Lorusso, Patricia
    Miller, Kathy D.
    Kao, Steven
    Kongpachith, Sarah
    Tribouley, Catherine
    Graham, Michelle
    Stoll, Brian
    Patel, Maulik
    Sahtout, Mohammad
    Blaney, Martha
    Leibman, Rachel
    Golan, Talia
    Tolcher, Anthony
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [40] Phase I study of SCH 900105 (SC), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb), as a single agent and in combination with erlotinib (E) in patients (pts) with advanced solid tumors.
    Patnaik, A.
    Weiss, G. J.
    Papadopoulos, K.
    Tibes, R.
    Tolcher, A. W.
    Tolcher, A. W.
    Cotreau, M. M.
    Jac, J.
    Isaacs, R.
    Ramanathan, R. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345